EUVIMEDEUVIMED entdecken
Open Access

Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer

Helen E Burston, Oliver A Kent, Laudine Communal, Molly L Udaskin, Ren X Sun, Kevin R Brown, Euihye Jung, Kyle E Francis, Jose La Rose, Joshua Lowitz, Ronny Drapkin, Anne-Marie Mes-Masson und 1 weitere

Journal of Clinical Investigation · 01.04.2021 · 131 (7)

DOI: 10.1172/jci142677 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.04.2021. Verfasst von Helen E Burston und 12 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Autocrine Communication, MAP Kinase Signaling System, Wnt Signaling Pathway. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autocrine CommunicationMAP Kinase Signaling SystemWnt Signaling PathwayAnimalsCarcinogenesisCell Line, TumorFemaleHumansMiceNeoplasm ProteinsOvarian NeoplasmsRelaxin

Stichwörter der Autor:innen

CancerG protein–coupled receptorsOncology

Substanzen

Neoplasm ProteinsRelaxin

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.
  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
  • Institut du Cancer de Montréal, Montréal, Quebec, Canada.
  • Banting and Best Department of Medical Research, Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada.
  • Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Antibody Solutions, Santa Clara, California, USA.

Förderung

  • CIHR

Zitieren

APA

Burston, H. E., Kent, O. A., Communal, L., Udaskin, M. L., Sun, R. X., Brown, K. R., Jung, E., Francis, K. E., La Rose, J., Lowitz, J., Drapkin, R., Mes-Masson, A. M., & Rottapel, R. (2021). Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. Journal of Clinical Investigation, 131(7). https://doi.org/10.1172/jci142677

Vancouver

Burston HE, Kent OA, Communal L, Udaskin ML, Sun RX, Brown KR, et al. Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. Journal of Clinical Investigation. 2021;131(7). doi:10.1172/jci142677

BibTeX
@article{Burston2021,
  author = {Burston, Helen E and Kent, Oliver A and Communal, Laudine and Udaskin, Molly L and Sun, Ren X and Brown, Kevin R and Jung, Euihye and Francis, Kyle E and La Rose, Jose and Lowitz, Joshua and Drapkin, Ronny and Mes-Masson, Anne-Marie and Rottapel, Robert},
  title = {Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer},
  journal = {Journal of Clinical Investigation},
  year = {2021},
  volume = {131},
  number = {7},
  doi = {10.1172/jci142677}
}
Kostenlos starten →